Purchase this article with an account.
A. M. Minnella, B. Falsini, A. Scupola, P. Sasso, L. Ziccardi, G. Stifano, L. Montrone, D. Marangoni, A. Mastrocola, E. Balestrazzi; Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2716.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the short-term effects of intravitreal bevacizumab injection on retinal function by focal electoretinogram (fERG) and microperimetry (MP1).
Twenty-one patients with exudative age related-macular degeneration (AMD) were treated with 0.125 mg/ml of intravitreal bevacizumab and evaluated, before and after injection, by best spectacle corrected visual acuity (BSCVA), fERGs to 8 Hz and 41 Hz flicker stimulation (central 18 degrees), MP1 sensitivity (central 10 degrees) and fixation stability. During 1-month follow-up, none of the patients underwent re-injection and the following parameters were considered: BSCVA, fERG 8 Hz 1st and 2nd harmonic response amplitude and 41 Hz 1st harmonic, MP1 sensitivity and 2° and 4° fixation stabillity.
When compared to baseline values, BSCVA, MP1 sensitivity and fixation stability improved (p < 0.001) at the end of study. No significant changes were observed for any of the FERG parameters. Significant positive correlations (r = 0.56; p < 0.01) were observed between microperimetry parameters and BSCVA at 30 days after injection.
Results suggest an improvement of central retinal function following intravitreal bevacizumab for AMD.
This PDF is available to Subscribers Only